Pfizer drug shows big promise in early testing for lung cancer patients with a certain gene
By Marilynn Marchione, APSaturday, June 5, 2010
Lung cancer drug shows big promise in early tests
CHICAGO — Doctors are reporting unusually high success rates from early tests of an experimental lung cancer drug.
The drug, called crizotinib, (crih-ZAH-tin-ib), is made by Pfizer Inc. It targets a gene that is found in about 4 percent of lung cancers, which amounts to 10,000 people a year in the United States alone.
In a study of 82 patients with advanced lung cancer, more than 90 percent saw their tumors shrink after two months on the drug.
Much more testing is needed to see if the drug is safe and effective. Researchers have already started a large study to test crizotinib against existing treatments. Results of the early testing were given at a cancer conference in Chicago Saturday.
Tags: Chicago, Diagnosis And Treatment, Diseases And Conditions, Lung Disease, Medication, North America, United States
|
June 11, 2010: 6:23 am
We make sure to provide you the best options for how to survive lung cancer. If you or someone close to you has been diagnosed with lung cancer, then this would be the right place for treatment of lung cancer. |
Lung Cancer Information